Short answer
Moderna (MRNA) filed an 8-K current report with the SEC on May 1, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Moderna reported financial results for Q1 ended March 31, 2026.
Moderna 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Moderna reported financial results for Q1 ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains the detailed results
- Disclosure furnished under Item 2.02, limiting Section 18 Exchange Act liability
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $389M, up $281M year over year, with $311M from international markets
- GAAP net loss $1.343B, including $0.9B litigation charge; EPS $(3.40) versus $(2.52)
- Settlement payment of $950M expected in Q3, pressuring liquidity despite non-cash Q1 recognition
- Cash and investments fell to $7.5B from $8.1B; year-end 2026 outlook $4.5B-$5.0B
- Management targets up to 10% 2026 revenue growth, supported by European mCOMBRIAX approval and late-stage pipeline catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Moderna 8-K filings
Get the next MRNA 8-K as it lands
Follow MRNA for push alerts, or ask the research agent what this filing means.